Business
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C., December 23, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment I
About this update from Precision Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/62b5291b66327089490eb99e57176727"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RMa4Q3prynKh9hDnW4gCqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/62b5291b66327089490eb99e57176727","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wndaE67kvgxUiro0iaVivA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/62b5291b66327089490eb99e57176727","width":1024,"height":512}},"lazy":false},{"type":"text","content":"DURHAM, N.C., December 23, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units ("RSUs") to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan ("Inducement Award Plan") in connection with their commencement of employment. The award was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.","length":775,"tagName":"p"},{"type":"text","content":"The employee’s RSUs vest (subject to continued service to Precision through the applicable vesting dates) in substantially equal annual installments on each of the first three anniversaries of the date of the commencement of their employment.","length":242,"tagName":"p"},{"type":"text","content":"About Precision BioSciences, Inc.","length":33,"tagName":"p"},{"type":"text","content":"Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using A...